England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the ...

A new Duke study is exploring whether cells inside the nose could reveal early signs of Alzheimer’s disease. Researchers say ...

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs - Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their ben ...

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

A recent study published in the journal Molecular Psychiatry provides evidence that a combination of non-invasive brain scanning and computer modeling can successfully measure how a dementia drug ...

Alzheimer's disease affects millions of people worldwide, yet the illness is hardest to catch at the very beginning, when new ...

Smith Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

Research roundtable highlights early detection, biomarkers, interventions ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

HHS Secretary Robert F. Kennedy Jr. appointed Michelle Branham as chair of the federal Advisory Council on Alzheimer’s ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.